regenicin page header biomedical collagen polymer header

Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.


Regenicin is playing a critical role in the development of the therapeutic candidate, NovaDerm™, a cultured cell technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.

show stock information

July 9,2015: Regenicin readying clinical trials of NovaDerm skin substitute
click to read artictle This takes you to the article on the BioTuesdays website. Lots of information about NovaDerm, photos, and a video.

March 3, 2015: Regenicin (RGIN) Receives $2.3 Million in
Final Payment from Amarantus

Company values the sale from the Asset Purchase Agreement at $8.023 million.